Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 6, November-December, p. 987–994

doi: 10.17219/acem/33811

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Expression of Proinflammatory Factors, Proangiogenic Factors and Endostatin in Patients with Heart Failure and Different Grades of Collateral Circulation Development

Małgorzata Kobusiak-Prokopowicz1,A,B,C,D, Beata Jołda-Mydłowska1,A,B,C, Tomasz Grzebieniak1,A,B, Karol Początek1,A,B, Andrzej Mysiak1,E,F

1 Department and Clinic of Cardiology, Wroclaw Medical University, Poland

Abstract

Background. The process of collateral vessel maturation is stimulated by numerous factors affecting the endothelium and smooth muscle cells building the vessel wall. Looking for arteriogenesis stimulating factors means looking for a potential innovative heart failure treatment method in the patients unresponsive to traditional therapies.
Objectives. The purpose of this study was to assess the changes in serum concentrations of pro-inflammatory factor IL-6, growth factors FGF (FGFa, FGFb, FGFbH), HGF, VEGF and endostatin in heart failure patients in relation to the coronary collaterals development stage.
Material and Methods. This study included 22 patients with chronic heart failure NYHA II or III (mean age 62.5 ± 11.6 years) and 8 control patients (mean age 58.4 ± 10.7 years). Coronary angiography was performed and the presence and grade of collateral circulation was assessed by a four-level scale proposed by Rentrop and Cohen. The level of the studied factors was determined in the blood samples collected during the angiographic procedure.
Results. The concentration of IL-6 was significantly higher in the heart failure patients than in the control group (p < 0.001) and in NYHA III vs. NYHA II patients (p < 0.02). Patients with heart failure and collaterals grade 1 or 2 exhibited higher serum concentrations of FGFbH (from p < 0.03 to p < 0.01). The serum VEGF level in NYHA III patients was significantly higher than in NYHA II individuals (from p < 0.03 to p < 0.01).
Conclusion. Higher levels of IL-6 and FGFbH were observed in patients with heart failure. Collaterals formation seems to be associated with the activation of pro-inflammatory factors, growth factors and endostatin.

Key words

arteriogenesis, proinflammatory factors, proangiogenic factors, endostatin, innovative treatment

References (27)

  1. Al Haj Zen A, Madeddu P: Notch signalling in ischemia-induced angiogenesis. Biochem Soc Trans 2009, 37, 1221–1229.
  2. Heilmann C, Beyersdorf F, Lutter G: Collateral growth: cells arrive at the construction site. Cardiovasc Surg 2002, 10, 570–578.
  3. Emanueli C, Madeddu P: Therapeutic angiogenesis: translating experimental concepts to medically relevant goals. Vasc Pharmacol 2006, 45, 334–339.
  4. Pipp F, Boehm S, Cai WJ, Adili F, Ziegler B, Karanovic G, Ritter R, Balzer J, Scheler C, Schaper W, Schmitz-Rixen T: Elevated fluid shear stress enhances postocclusive collateral artery growth and gene expression in the pig hind limb. Arterioscler Thromb Vasc Biol 2004, 24, 1664–1668.
  5. Schierling W, Troidl K, Troidl C, Schmitz-Rixen T, Schaper W, Eitenmüller IK: The role of angiogenic growth factors in arteriogenesis. J Vasc Res 2009, 46, 365–374.
  6. Buschmann I, Heil M, Jost M, Schaper W: Influence of inflammatory cytokines on arteriogenesis. Microcirculation 2003, 10, 371–379.
  7. Griffioen AW, Molema G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52, 237–268.
  8. Tabibiazar R, Rockson SG: Angiogenesis and the ischaemic heart. Eur Heart J 2001, 22, 903–918.
  9. Chung NA, Lydakis C, Belgore F: Angiogenesis in myocardial infarction. An acute or chronic process? Eur Heart J 2002, 23, 1604–1608.
  10. Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL: Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol 2004, 43, 1383–1387.
  11. Charney R, Cohen M: The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. Am Heart J 1993, 126, 937–945.
  12. Lahteenvuo JE, Lahteenvuo MT, Kivela A, Rosenlew C, Falkevall A, Klar J, Heikura T, Rissanen TT, Vahakangas E, Korpisalo P, Enholm B, Carmeliet P, Alitalo K, El-Melegy NT, Mohamed NA: Angiogenic biomarkers in children with congenital heart disease: possible implications. Ital J Pediatr 2010, 36, 32.
  13. Cohen M, Rentrop KP: Limitation of myocardial ischaemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects. A prospective study. Circulation 1974, 469, 1986–1992.
  14. Rentrop KP, Feit F, Sherman W, Thornton JC: Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial. Circulation 1989, 80, 1166–1175.
  15. Pipp F, Boehm S, Cai WJ, Adili F, Ziegler B, Karanovic G, Ritter R, Balzer J, Scheler C, Schaper W, Schmitz-Rixen T: Elevated fluid shear stress enhances postocclusive collateral artery growth and gene expression in the pig hind limb. Arterioscler Thromb Vasc Biol 2004, 24, 1664–1668.
  16. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994, 15, 74–80.
  17. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ: Tissue cytokine patterns in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med 1994, 121, 484–491.
  18. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC: Tissue production of proinflammatory cytokines (IL-1ß, TNF-{alpha}, and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004, 43, 294–301.
  19. Mantovani A, Garlanda C, Introna M, Vecchi A: Regulation of endothelial cell function by proand anti-inflammatory cytokines. Transplant Proc 1998, 30, 4239–4243.
  20. Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A: Prostacyclin synthesis induced by in vascular cells by interleukin-1. Science 1985, 225, 174–176.
  21. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G: Angiogenesis and hematopoiesis induced by Kaposi-sarcoma-associated herpes-virus encoded interleukin-6. Blood 1999, 93, 4034–4043.
  22. Zhong Z, Wen Z, Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264, 95–98.
  23. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F: In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 2002, 16, 225–227.
  24. El-Melegy NT, Mohamed NA: Angiogenic biomarkers in children with congenital heart disease: possible implications. Ital J Pediatr 2010, 36, 32.
  25. Patel JV, Abraheem A, Chackathayil J, Gunning M, Creamer J, Hughes EA, Lip GY: Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. J Intern Med 2009, 265, 562–567.
  26. Furlani AP, Kalil RA, Castro I, Canedo-Delgado A, Barra M, Prates PR, Sant`Anna RT, Nesralla IA: Effects of therapeutic angiogenesis with plasmid VEGF165 on ventricular function in a canine model of chronic myocardial infarction. Rev Bras Cir Cardiovasc 2009, 24, 143–149.
  27. Hedman M, Muona K, Hedman A, Kivelä A, Syvänne M, Eränen J, Rantala A, Stjernvall J, Nieminen MS, Hartikainen J, Ylä-Herttuala S: Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009, 16, 629–634.
© Wroclaw Medical University